Format

Send to

Choose Destination
Am J Hosp Palliat Care. 2015 Feb;32(1):5-7. doi: 10.1177/1049909113504240. Epub 2013 Sep 19.

Dronabinol treatment of refractory nausea and vomiting related to peritoneal carcinomatosis.

Author information

1
University of South Florida College of Medicine, Tampa, FL, USA.
2
University of South Florida College of Medicine, Tampa, FL, USA Hospice and Palliative Care Unit, James A. Haley VA Hospital, Tampa, FL, USA.
3
Hospice and Palliative Care Unit, James A. Haley VA Hospital, Tampa, FL, USA.
4
University of South Florida College of Medicine, Tampa, FL, USA Hospice and Palliative Care Unit, James A. Haley VA Hospital, Tampa, FL, USA jonathan.stewart1@va.gov.

Abstract

Nausea and vomiting are common and often highly distressing symptoms in advanced cancer and in hospice and palliative medicine practice. Nausea and vomiting generally respond well to correction of the underlying etiology (when possible) and appropriate selection of antiemetic medication, but up to 7% of patients will have refractory symptoms. Dronabinol is extensively studied for chemotherapy-related nausea and vomiting, but there are only a few case reports of its use in nausea and vomiting unrelated to chemotherapy. We report a patient with end-stage ovarian cancer with peritoneal carcinomatosis and refractory nausea and vomiting who responded dramatically to addition of dronabinol. Dronabinol is usually well tolerated and may have several novel mechanisms of antiemetic action; further study of its scope of efficacy is warranted.

KEYWORDS:

anandamide; dronabinol; endocannabinoids; nausea; ovarian cancer; peritoneal carcinomatosis; vomiting

PMID:
24052427
DOI:
10.1177/1049909113504240
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center